Jose Zamorano

List of Publications by Year
in descending order

30 papers	2,133 citations	471509 17 h-index	477307 29 g-index
31 all docs	31 docs citations	31 times ranked	3056 citing authors

#	Article	IF	Citations
1	Proton pump inhibitors and risk for recurrent ischemic events or death in outpatients with symptomatic artery disease. Atherosclerosis, 2020, 292, 84-89.	0.8	6
2	Multivariate analysis for coronary heart disease in heterozygote familial hypercholesterolemia patients. Personalized Medicine, 2018, 15, 87-92.	1.5	4
3	IL-4 and IL-13 Receptor Signaling From 4PS to Insulin Receptor Substrate 2: There and Back Again, a Historical View. Frontiers in Immunology, 2018, 9, 1037.	4.8	32
4	Response to Ishimura et al.. American Journal of Gastroenterology, 2016, 111, 1204-1205.	0.4	0
5	Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis. American Journal of Gastroenterology, 2015, 110, 1567-1575.	0.4	102
6	rs1801275 Interleukin-4 receptor alpha polymorphism in familial hypercholesterolemia. Journal of Clinical Lipidology, 2014, 8, 418-422.	1.5	2
7	Effectiveness of Three Sleep Apnea Management Alternatives. Sleep, 2013, 36, 1799-1807.	1.1	29
8	Significance of Including a Surrogate Arousal for Sleep Apnea-Hypopnea Syndrome Diagnosis by Respiratory Polygraphy. Sleep, 2013, 36, 249-257.	1.1	16
9	Distinguishing Eosinophilic Esophagitis from Gastroesophageal Reflux Disease upon PPI Refractoriness: What about PPI-Responsive Esophageal Eosinophilia. Digestion, 2012, 85, 210-210.	2.3	9
10	Influence of Lipoprotein (a) on Inflammatory Biomarkers in Metabolic Syndrome. Southern Medical Journal, 2012, 105, 339-343.	0.7	8
11	Peripheral Arterial Disease: Efficacy of the Oscillometric Method. Revista Espanola De Cardiologia (English Ed), 2011, 64, 619-621.	0.6	8
12	Concomitant Use of Proton Pump Inhibitors and Clopidogrel in Patients With Coronary, Cerebrovascular, or Peripheral Artery Disease in the Factores de Riesgo y ENfermedad Arterial (FRENA) Registry. Journal of Cardiovascular Pharmacology, 2011, 57, 13-19.	1.9	25
13	Telmisartan Improves Insulin Resistance in Patients with Low Cytokine Levels. Journal of Investigative Medicine, 2011, 59, 602-605.	1.6	3
14	Vertebral Fractures. New England Journal of Medicine, 2011, 365, 673-674.	27.0	1
15	Therapeutic Decision-making for Sleep Apnea and Hypopnea Syndrome Using Home Respiratory Polygraphy. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 964-971.	5.6	75
16	Ankle-Brachial Index Measurement in the Primary Care Setting. Southern Medical Journal, 2010, 103, 590.	0.7	1
17	Adverse drug reactions in internal medicine units and associated risk factors. European Journal of Clinical Pharmacology, 2010, 66, 1257-1264.	1.9	44
18	Omeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma. Journal of Allergy and Clinical Immunology, 2009, 124, 607-610.e1.	2.9	52

#	Article	IF	Citations
19	Treatment of cells with n-alpha-tosyl-l-phenylalanine-chloromethyl ketone induces the proteolytic loss of STAT6 transcription factor. Molecular Immunology, 2008, 45, 3896-3901.	2.2	7
20	Kaempferol Inhibits IL-4-Induced STAT6 Activation by Specifically Targeting JAK3. Journal of Immunology, 2007, 179, 3881-3887.	0.8	66
21	Proteolytic Regulation of Activated STAT6 by Calpains. Journal of Immunology, 2005, 174, 2843-2848.	0.8	22
22	Phosphatidylcholine-Specific Phospholipase C Activity Is Necessary for the Activation of STAT6. Journal of Immunology, 2003, 171, 4203-4209.	0.8	13
23	Aspirin and Salicylates Inhibit the IL-4- and IL-13-Induced Activation of STAT6. Journal of Immunology, 2002, 168, 1428-1434.	0.8	61
24	NF-Î¤B activation plays an important role in the IL-4-induced protection from apoptosis. International Immunology, 2001, 13, 1479-1487.	4.0	36
25	Costimulation of resting B lymphocytes alters the IL-4-activated IRS2 signaling pathway in a STAT6 independent manner: implications for cell survival and proliferation. Cell Research, 2001, 11, 44-54.	12.0	19
26	THE IL-4 RECEPTOR: Signaling Mechanisms and Biologic Functions. Annual Review of Immunology, 1999, 17, 701-738.	21.8	1,373
27	A Role for the Insulin-Interleukin (IL)-4 Receptor Motif of the IL-4 Receptor Î±-Chain in Regulating Activation of the Insulin Receptor Substrate 2 and Signal Transducer and Activator of Transcription 6 Pathways. Journal of Biological Chemistry, 1998, 273, 9898-9905.	3.4	29
28	HMG-I(Y) Phosphorylation Status as a Nuclear Target Regulated through Insulin Receptor Substrate-1 and the I4R Motif of the Interleukin-4 Receptor. Journal of Biological Chemistry, 1997, 272, 25083-25090.	3.4	25
29	Requirement of a second signal via protein kinase C or protein kinase A for maximal expression of CD40 ligand. Involvement of transcriptional and posttranscriptional mechanisms. European Journal of Immunology, 1997, 27, 2822-2829.	2.9	35
30	Upregulated expression of IL-4 receptors and increased levels of IL-4 in rheumatoid arthritis patients. Journal of Autoimmunity, 1995, 8, 587-600.	6.5	30